Drug intelligence / Profile preview

MB-201

Development stage: Preclinical
Lead developer: Mainline Biosciences
Modality: Small Molecules

Overview

MB-201 is a drug developed by Mainline Biosciences, Inc. It is currently in preclinical development for the treatment of obesity. Its mechanism of action involves acting as an agonist for both the Melanocortin receptor 4 (MC4R) and the Oxytocin receptor (OXTR).

Targets

MC4R (Melanocortin 4 receptor)Oxytocin receptor

Beyond the preview

Go deeper on MB-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MB-201.

Explore the full profile